Answers are grounded in this paper and cite their sources.
Compares overall survival in advanced nonsquamous lung cancer, implying nivolumab may be more effective.
Among patients with advanced nonsquamous NSCLC that had progressed during or after platinum-based chemotherapy, overall survival was longer with nivolumab than with docetaxel. (Funded by Bristol-Myers Squibb; CheckMate 057 ClinicalTrials.gov number, NCT01673867.).
No takes yet. Share an insight, caveat, or question.
Borghaei et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: